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Pharmacological studies have suggested that MDD is associated with an impairment of brain neurotransmitters. The role of serotonin (5-HT), which is based mainly on the efficacy of selective and nonselective 5-HT reuptake inhibitors in the treatment of MDD, was reviewed by Maes and Meltzer. 3 Dopamine (DA), has also been implicated in the pathophysiology of mood disorders and hypoactivity of the mesolimbic DA pathway may be connected to depressive symptoms. 4 Thus, genes that control the brain 5-HT and DA pathways seem to be good candidates for mediating genetic susceptibility to MDD.
Association of polymorphisms in seven genes from the serotonergic and dopaminergic pathways was studied in 102 unipolar patients and 172 healthy control subjects. The patient population was subdivided according to ethnic origin (63 Ashkenazi and 39 nonAshkenazi Jews) and compared to the corresponding group of mentally healthy controls. The distribution of genotypes and alleles in the different populations is shown in Table 1 . Comparison of healthy individuals of Ashkenazi and non-Ashkenazi origin revealed that although frequencies of genotypes and alleles showed some differences, they did not reach statistical significance. Nevertheless, in order to avoid possible errors caused by population stratifications we compared the patients with their ethnic counterparts.
When unipolar MDD patients were compared to healthy controls of the same ethnic origin (Table 1) , the distribution of genotypes and alleles of the seven polymorphisms studied (TPH, HTR2A, HTR2C, 5-HTTLPR, DAT1, DRD4 and COMT) did not show statistically significant differences.
Molecular genetic studies in mood disorders performed thus far, have focused mainly on bipolar depression (BPI and BPII). Association studies of unipolar depression with several polymorphisms were performed previously with conflicting results. The allelic distribution of the insertion/deletion polymorphism in the promoter region of the serotonin transporter (5-HTTLPR) in MDD patients was investigated by several groups of researchers. Our results are similar to those of Kunugi et al, 5 Rees et al, 6 Furlong et al 7 and Hoehe et al, 8 who found no association of this polymorphism with unipolar MDD in Japanese, UK and West European populations respectively. In contrast, a European multi-center study (Collier et al 9 ) and a metaanalysis of individuals of European Caucasian origin 7 reported an increased frequency of the short allele in bi-and unipolar depressed patients, whereas a decrease of this allele was reported in a subgroup of unipolar probands. 6 The fact that three different results were obtained in different populations, shows that these associations may be the result of a linkage disequilibrium with as yet unknown population-specific mutations, rather than a consequence of the proposed biological activity of the different alleles. 9 With regard to the other components of the serotonergic system, Zhang et al, 10 found an increase in the T102 allele of HTR2A (C1 allele in our terminology) in unipolar depressed patients. We also noted such an increase, but it was not statistically significant. The lack of association of TPH with unipolar depression in the present study is in accordance with the results of Furlong et al. 11 Manki et al 12 reported an association between the DRD4 alleles and major depression in Japanese subjects, with a decrease in allele 4 and an increase in allele 5 in the patient population. Oruc et al 13 found no association of recurrent unipolar depression with DRD4 alleles in a Croatian population. In our study, overall differences in allelic distribution did not reach statistical significance, although a trend of an increase of allele 2 and a decrease of allele 7 in depressed patients was noted. This might be just a spurious result but, if replicated in a larger sample it may support the notion that large alleles of DRD4 are associated with 'novelty seeking' traits. Ohara et al 14 found an association of the low activity allele of COMT with depressive disorder in Japanese patients. We could not replicate this finding in our sample. To our knowledge no association studies of unipolar disorder were performed with the serotonin receptor 2C (HTR2C) and dopamine transporter (DAT1).
In this study we divided the Israeli-Jewish population into two ethnic groups of Ashkenazi and nonAshkenazi origin. On the one hand, it created smaller study groups thus reducing the statistical power but on the other, created a genetically more homogenous population helping to reduce artifacts stemming from population stratification.
The fact that we had tested our sample with a relatively large number of candidate genes, allowed us to explore the role of both serotonergic and dopaminergic genes in depression. The drawback of such study design is that testing more parameters entails stringent statistical requirements thus increasing the risk of a type II error of overlooking genuine effects. 15 In summary, our study does not support a major role for any of the polymorphisms studied in unipolar MDD patients of Ashkenazi and non-Ashkenazi origin. This does not imply that polymorphisms in serotonergic and dopaminergic genes do not contribute to the susceptibility to MDD, but rather that we should expect minor effects, probably synergistic, dependent on a combination of genes. Future studies should include larger samples of patients and controls from genetically homogeneous populations or employ family-based methods such as the Transmission Disequilibrium Test (TDT) which correct for population stratification.
Methods

Subjects
Patient population included 102 biologically unrelated unipolar MDD probands (63 Ashkenazi and 39 nonAshkenazi Jews) and 172 mentally and physically healthy control subjects (112 Ashkenazi and 60 non-Ashkenazi Jews). Individuals were considered to be of Ashkenazi-Jewish origin if all four grandparents originated from Europe. Patients were recruited from three mental health centers. All subjects (patients and controls) were interviewed by trained psychiatrists (DP, SP, EB) with the Schedule for Affective Disorders and Schizophrenia-Lifetime Version (SADS-L) 16 or the Structured Clinical Interview for DSM-IV-Patient Version (SCID). 17 The study was approved by the Institutional Review Board and all participants signed an informed consent.
DNA extraction
Blood samples (15 ml) were collected from all participants. DNA was extracted from leukocytes by the salting out procedure 18 and stored at −20°C.
Detection of polymorphisms
Tryptophan hydroxylase (TPH) DNA was amplified with primers from intron 7 of the TPH gene. 19 The PCR product (880 bp) was digested by BfaI (New England Biolabs, Beverly, MA, USA) and then separated on 1% agarose gel. The allele that contained the restriction site was designated 'C' and the allele that did not was designated 'A'.
Serotonin 2A receptor (HTR2A)
A genomic DNA fragment corresponding to nucleotides −24 to 318 of the serotonin receptor was amplified by PCR. Digestion of the 342-bp PCR product with MspI yields one fragment for allele C1 and two fragments for allele C2. 20 
Serotonin 2C receptor (HTR2C)
The two alleles of HTR2C (Cys 23 and Ser 23) were revealed by creating an artificial restriction site near the codon of interest and detection of this site by Hinf I. 21 PCR products were separated using a mixture of 2% agarose and 2% Nusieve (low-melting agarose).
Serotonin transporter (promoter region) (5-HTTLPR)
The insertion/deletion polymorphism in the promoter of the serotonin transporter gene was studied according to Lesch et al. 22 The GC-rich region was amplified with Pfu exo minus DNA polymerase in the presence of 7-Deaza-dGTP. The two amplification products were separated on 2% agarose gel and classified as long (528 bp) and small (484 bp) alleles.
Dopamine D4 receptor (DRD4)
The 48-bp repeats in the third cytoplasmic loop of the receptor give rise to nine alleles varying from two to 10 repeats. Primers suggested by Lichter et al 23 were used and PCR conditions adapted to high GC content: Pfu exo minus polymerase, 7-Deaza-dGTP and denaturation temperature of 98°C. The different alleles were separated on 2% agarose gels.
Dopamine transporter (DAT1)
A 40-bp VNTR is present in the 3Ј untranslated region of the human DAT gene. It has seven alleles ranging from three to 11 repeats. PCR conditions were as described by Vandenbergh et al. 24 
Catechol-O-methyltransferase (COMT)
The high and low-activity alleles in exon 4 (codon 158) were detected by amplification of a 169-bp fragment according to Lachman et al, 25 and subsequent digestion with NlaIII. The presence of the restriction site identified the low-activity allele (B) and in its absence the high-activity allele (A).
Statistical analysis
The chi-square method with Yate's correction was used to test the statistical significance of the differences in the distribution of the alleles between patients and their ethnically matched controls. Since we performed multiple tests the Bonferroni correction was used and the significance level was set at P = 0.003.
